Lexaria Bioscien Stock Price, News & Analysis

Lexaria Bioscience (NASDAQ:LEXX) has achieved the Last Patient Last Visit (LPLV) milestone in its Phase 1b GLP-1 study in Australia. The study, designated as GLP-1-H24-4, is currently in the laboratory analysis phase where thousands of samples are being processed and analyzed.

The company previously reported positive 8-week interim results showing encouraging safety and tolerability data compared to the Rybelsus® control arm, particularly noting reduced gastrointestinal adverse events. The final report is expected in late 2025.

Lexaria Bioscience (NASDAQ:LEXX) provides an update on the expanding GLP-1 and obesity drug market, highlighting its DehydraTECH technology's potential role. The market is expected to exceed $150 billion by 2030, with 39 new GLP-1 drugs in development from 34 companies.

The company's DehydraTECH platform has demonstrated significant reductions in gastrointestinal adverse events across major GLP-1 drugs, showing improvements ranging from 31% to 100% in various studies. The update also details recent major industry deals, including Novo Nordisk's $2.2 billion collaboration with Septerna, Roche's $5.3 billion rights acquisition from Zealand Pharma, and Regeneron's $1.93 billion licensing deal with Hansoh Pharmaceutical.

Lexaria Bioscience (NASDAQ:LEXX) has reported positive interim 8-week results from its Phase 1b GLP-1-H24-4 study comparing DehydraTECH-enhanced semaglutide and tirzepatide to Rybelsus®. The study revealed that DehydraTECH-semaglutide reduced overall adverse events by 36.5% and gastrointestinal side effects by 43.5% compared to Rybelsus®.

Key findings show that only 79.2% of DehydraTECH-semaglutide patients experienced adverse events, compared to 100% in the Rybelsus® group. For weight loss, DehydraTECH-semaglutide showed a reduction of 1.23% after 8 weeks, while HbA1c levels decreased by 0.14%. The study is expected to complete with final results by the end of 2025.

Lexaria Bioscience (NASDAQ:LEXX) positions its DehydraTECH technology as a potential solution for the GLP-1 industry's biggest challenge: adverse effects. The GLP-1 market is experiencing remarkable growth, with projected revenues increasing from $53.5 billion in 2024 to $70.1 billion in 2025, and expected to reach $156 billion by 2030.

However, 47-64% of GLP-1 users discontinue treatment within 1-2 years, primarily due to gastrointestinal side effects. Notably, 75.7% of patients experience gastrointestinal adverse events with leading GLP-1 drugs. Lexaria's DehydraTECH technology has demonstrated in human clinical testing its ability to reduce side effects in the top three GLP-1 drugs: semaglutide, tirzepatide, and liraglutide.

The company is currently collaborating with a pharmaceutical partner ("PharmaCO") under a material transfer agreement announced in September 2024 to evaluate DehydraTECH compositions.

Lexaria Bioscience (NASDAQ: LEXX) has achieved a significant milestone by securing its 50th worldwide patent, with two new international patents granted. The company received a patent in Australia for epilepsy treatment technology (patent family #24) expiring in 2044, and another in Japan for sublingual nicotine delivery (patent family #20) expiring in 2043. The epilepsy drug market, valued at $9.5B in 2023, is projected to reach $15B by 2032, affecting 50M people in the US. The global retail oral nicotine market, valued at $5.5B in 2023, is expected to grow 26% annually until 2030, with the nicotine pouch market reaching $25.4B by 2030. Altria Ventures Inc., holding 16.67% of Lexaria Nicotine LLC, maintains a non-exclusive license for DehydraTECH with nicotine products.

Lexaria Bioscience (NASDAQ: LEXX) has successfully completed a human clinical study comparing oral DehydraTECH-liraglutide capsules to injectable Saxenda (liraglutide). The study demonstrated a 22.7% overall reduction in adverse events with the oral formulation, including significant decreases in nausea (67%) and gastrointestinal issues (31%). The oral version showed comparable effectiveness in blood glucose, insulin, and weight loss metrics. This breakthrough positions Lexaria to pursue FDA registration through the 505(b)(2) pathway for an oral alternative to injectable liraglutide, which generated $1.8B in revenue for Novo Nordisk in 2024. Notably, Lexaria has now shown reduced adverse events with DehydraTECH versions of all three major GLP-1 drugs: liraglutide, semaglutide, and tirzepatide.

Lexaria Bioscience Corp. (NASDAQ: LEXX) announced its participation in the BIO International Convention, scheduled for June 16-19 in Boston. As the world's largest biotechnology convention, BIO will host over 1,500 exhibitors and 20,000 attendees. Lexaria's CEO and President, along with the Chief Scientific Officer, will attend the event to explore potential partnerships and meet with strategic investors. The company aims to advance discussions regarding its DehydraTECH-enhanced drug product candidates, focusing on weight loss, diabetes, and hypertension treatments. Lexaria is currently scheduling one-on-one meetings with global and regional corporate leaders through the BIO Partnering platform.

Lexaria Bioscience Corp. (NASDAQ: LEXX) has provided an update on its Material Transfer Agreement (MTA) with an unnamed pharmaceutical company (PharmaCO). The company has completed initial pre-clinical pharmacokinetic animal studies evaluating Lexaria's DehydraTECHTM technology, though results will remain confidential. PharmaCO has expressed interest in reviewing pending safety and efficacy data from Lexaria's ongoing independent human study GLP-1-H24-4 in Australia, expected in Q3 2025.

Lexaria is preparing for strategic planning discussions with PharmaCO's human clinical development team regarding potential collaborative human clinical studies. Both parties have agreed to maintain their relationship and keep the temporary exclusive license active until the Australian study data becomes available.

Lexaria Bioscience (NASDAQ: LEXX) has successfully closed a $2 million registered direct offering of common stock with a single institutional investor. The deal was structured at $1.00 per share for 2,000,000 shares, with an option for pre-funded warrants in lieu of shares.

Key highlights of the offering:

• H.C. Wainwright & Co. served as the exclusive placement agent
• The offering was made under an effective S-3 shelf registration
• No additional warrants were issued except for pre-funded warrants
• Net proceeds will support working capital and general corporate purposes

CEO Richard Christopher emphasized the achievement of securing funding in challenging market conditions while minimizing shareholder dilution by avoiding additional warrant issuance. The offering was completed through a shelf registration statement that received SEC approval on January 30, 2025.